Breast Cancer Research and Treatment最新文献

{"title":"Association between cumulative symptom burden and cognitive impairment among breast cancer survivors: a cross-sectional study.","authors":"Xiaotong Li, Kaitlin Lampson, Kevin T Liou, Yuelin Li, Susan Q Li, Tim Ahles, James Root, Jun J Mao","doi":"10.1007/s10549-026-08064-7","DOIUrl":"10.1007/s10549-026-08064-7","url":null,"abstract":"<p><strong>Background: </strong>Cancer-related cognitive impairment (CRCI) is a multifaceted symptom associated with various comorbid conditions, complicating management. This study aims to evaluate cumulative symptom burden and its impact on both subjective and objective CRCI in breast cancer survivors.</p><p><strong>Method: </strong>Enrollment data were analyzed from a randomized clinical trial involving women with stage 0-III breast cancer, free of oncology disease, reporting moderate or greater CRCI and insomnia. Subjective CRCI was measured using the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), and objective CRCI with the Hopkins Verbal Learning Test-Revised (HVLT). Comorbid symptoms (insomnia, fatigue, pain, anxiety, depression) were assessed with validated self-report tools. A Cumulative Symptoms Score (CSS) was calculated to quantify symptom burden. Multivariable linear regression was used to examine associations with CRCI, adjusting for co-variables.</p><p><strong>Results: </strong>Among 260 participants (mean age 56.6 years), 21% were non-White and 10% Hispanic. Fatigue (90%) was the most common, followed by insomnia (70%), pain (45%), anxiety (35%), and depression (12%). Higher CSS was significantly associated with worse subjective CRCI after adjustment for age and chemotherapy (Coef. = -3.0, 95% CI: -3.6 to -2.4, p < 0.001). Each comorbid symptom was correlated with subjective CRCI (all p < 0.001). CSS was not associated with objective cognitive performance (p = 0.58), although insomnia correlated with HVLT scores (r = -0.20; p < 0.001).</p><p><strong>Conclusion: </strong>Cumulative symptom burden was associated with subjective but not objective CRCI. Comprehensive symptom management has the potential to improve subjective appraisal of CRCI. Sleep disturbance may be a therapeutic target for improving objective outcomes.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"219 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study.","authors":"Brian Lee, Bethania Santos, Heather McArthur, Alexis LeVee, Austin Kordic, Song Zhang, Joshua J Gruber","doi":"10.1007/s10549-026-08074-5","DOIUrl":"10.1007/s10549-026-08074-5","url":null,"abstract":"<p><strong>Introduction: </strong>Multi-agent neoadjuvant therapy (NAT) with immune checkpoint blockade is standard treatment for Stage II-III triple-negative breast cancer (TNBC), though its role in smaller node-negative tumors remains unclear.</p><p><strong>Methods: </strong>We performed a retrospective multi-institutional cohort study evaluating demographics, treatment patterns, and outcomes in a contemporary \"small TNBC\" population (n = 215) comprising Stage I (n = 154) and Stage II, T < 3 cm TNBC (n = 61).</p><p><strong>Results: </strong>Within the small TNBC cohort, Stage II, < 3 cm tumors demonstrated higher rates of grade 3 histology (93.4% vs 74.7%, p = 0.0013), NAT (85.2% vs 61.0%, p = 0.0006), adjuvant pembrolizumab (56.8% vs 24.7%, adjusted p = 0.0024), and neoadjuvant KEYNOTE-522 (75.0% vs 45.7%, adjusted p = 0.0052) compared with Stage I disease. Despite these treatment differences, recurrence and mortality rates were similar between groups. Among NAT-treated patients with small TNBC (n = 146), the pathologic complete response (pCR) rate was 51.3% (75/146), without significant difference between Stage I and Stage II, < 3 cm tumors (51.1% vs 51.9%, p = 0.92). There were no significant differences in regimen-specific pCR rates or event-free survival (EFS) when comparing NAT between Stage I and Stage II, < 3 cm tumors, or comparing NAT vs. no NAT for the small TNBC cohort.</p><p><strong>Conclusions: </strong>Stage I and Stage II, < 3 cm TNBC demonstrated overlapping clinicopathologic features, pCR rates, and short-term survival outcomes despite substantially different treatment approaches. These findings suggest that current stage-based treatment distinctions may not fully capture the clinical behavior of small TNBC and support further prospective evaluation of risk-adapted and size-based treatment frameworks to better individualize NAT selection in this understudied population.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"219 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.","authors":"F Schochter, T W P Friedl, H Schäffler, F Meier-Stiegen, K N Pfister, S Riethdorf, L Wiesmüller, H Neubauer, L Müller, P Wimberger, P A Fasching, R Lorenz, T Hempel, S Heublein, A Hartkopf, K Pantel, B Rack, V Müller, T Fehm, W Janni, J P Cieslik","doi":"10.1007/s10549-026-08069-2","DOIUrl":"10.1007/s10549-026-08069-2","url":null,"abstract":"<p><strong>Background: </strong>Eribulin is a non-taxane microtubule inhibitor that showed survival benefits for pretreated metastatic breast cancer (MBC) patients. Circulating tumor cells (CTCs) are a prognostic marker, but their role in predicting response to specific MBC treatments is less clear. In this trial, we assessed the clinical outcome and its association with CTC-dynamics in HER2-negative MBC treated with eribulin.</p><p><strong>Patients and methods: </strong>HER2-negative MBC-patients were screened for CTCs within the DETECT study program using the CellSearch® technology (Menarini Silicon Biosystems; Bologna, Italy). Patients with HER2-negative CTCs were eligible for the single-arm DETECT-IVb study treatment with eribulin. Primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), CTC-clearance rate and safety.</p><p><strong>Results: </strong>Median PFS and OS were 4.6 months and 13.4 months, respectively. Multivariable adjusted analyses showed that patients with CTC-clearance at first follow-up (34.7%) had significantly improved PFS (p = 0.043) but not OS (p = 0.192) compared to patients with at least 1 CTC. Likewise, patients with CTC-clearance at the end of the treatment (23.1%) achieved a significantly better PFS (p = 0.015) but not OS (p = 0.218). Neutropenia, leukopenia, anemia and fatigue were the most common adverse events and no new or unexpected safety signals were obtained.</p><p><strong>Conclusion: </strong>In this trial, we could confirm eribulin as an effective treatment option in high-risk HER2-negative MBC. CTCs proved their role as a prognostic marker and our results support the potential role of CTC dynamics as an early biomarker of treatment response to eribulin.</p><p><strong>Trial registration: </strong>EudraCTNo2013-001269-18 http://ClinicalTrials.gov , TRN NCT02035813, Registration date 2014-01-12.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"219 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13582096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrin α2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model.","authors":"Ibrahim Ragab Eissa, Yongtao Wang, Kenneth K Tanabe","doi":"10.1007/s10549-026-08077-2","DOIUrl":"https://doi.org/10.1007/s10549-026-08077-2","url":null,"abstract":"<p><strong>Introduction: </strong>Collagen is a defining feature of breast tumors and is increasingly recognized as a regulator of tumor progression and immune exclusion. However, the tumor cell-matrix interaction that link collagen sensing to immune suppression remains poorly understood.</p><p><strong>Objectives: </strong>The primary objective of this study was to identify the role of integrin α2 (CD49b/ITGA2) in promoting collagen-dependent tumor growth and immune evasion in breast cancer.</p><p><strong>Methods & results: </strong>Integrated bulk and single cell transcriptomic analyses reveal that ITGA2 is broadly expressed across breast cancer subtypes and is preferentially localized to malignant epithelial cells. Functional assays demonstrate that CD49b is a dominant receptor mediating breast cancer cell adhesion to collagen I and IV. Genetic ablation or antibody-mediated blockade of CD49b suppresses tumor growth in vivo and profoundly remodels the tumor immune microenvironment, characterized by increased infiltration of CD8⁺ T cells and antigen-presenting dendritic cell subsets, alongside reduced immunosuppressive myeloid populations. Consistent with these findings, ITGA2 expression in human breast cancer cohorts correlates with stromal enrichment and immune exclusion signatures. Importantly, CD49b blockade synergizes with PD-L1 immune checkpoint inhibition, enhancing T cell activation, effector function, and tumor control.</p><p><strong>Conclusions: </strong>Together, these results identify CD49b mediated tumor collagen interactions as a key driver of immune suppression and resistance to immunotherapy, and provide a mechanistic rationale for targeting integrin α2β1 to enhance antitumor immunity in the 4T1 breast cancer model.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"219 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in contralateral prophylactic mastectomy and genetic testing in the era of new society guidelines.","authors":"Anna M Reagan, Christina R Rutherford, Saranya Prathibha, Brittany E Levy, Corinne Praska, Sarah E Thacker, Madison Kolbow, Bethel Ozed-Williams, Kelsey N Karnik, Anthony A Mangino, Schelomo Marmor, Todd M Tuttle, Jane Yuet Ching Hui, Erin E Burke","doi":"10.1007/s10549-026-08073-6","DOIUrl":"https://doi.org/10.1007/s10549-026-08073-6","url":null,"abstract":"<p><strong>Purpose: </strong>In 2016 and 2019 respectively, the American Society of Breast Surgeons published consensus statements discouraging contralateral prophylactic mastectomy (CPM) in average-risk women with unilateral breast cancer and recommending genetic testing be made available for all patients with breast cancer. We sought to evaluate trends in CPM and genetic testing across two academic healthcare systems before and after the publication of the 2016 statement.</p><p><strong>Methods: </strong>Retrospective chart review was performed from 2011 to 2020 for women with newly diagnosed unilateral stage 0 to III breast cancer who underwent surgery. Patients treated at the University of Kentucky or within the academic health system at the University of Minnesota were included and divided into two cohorts: before the 2016 CPM publication and after. Rates of CPM and genetic testing and factors associated with CPM were evaluated.</p><p><strong>Results: </strong>6,203 patients were identified. 2,619 patients were diagnosed between 2011 and 2015, and 3,584 were diagnosed between 2016 and 2020. Genetic testing was higher in the later cohort, with 2% prior to 2016 and 22% in 2016 or later. Rates of CPM were similar in the earlier and later cohorts (19% and 15%, respectively; p < 0.001). Factors associated with receipt of CPM were younger age, white race, lobular histology, increasing tumor size, HER2 positivity and genetic testing.</p><p><strong>Conclusion: </strong>CPM trends at two academic institutions remained relatively stable over a time period when societal guidelines discouraged the use of CPM in average-risk women with unilateral breast cancer. Further work to understand these trends and identify interventions to reduce the rates of CPM is needed.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"219 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018-2024.","authors":"Jane Meisel, Tim Pham, Clara Chen, Ayush Kris, James Roose","doi":"10.1007/s10549-026-08060-x","DOIUrl":"10.1007/s10549-026-08060-x","url":null,"abstract":"<p><strong>Purpose: </strong>To understand historical and recent ESR1 testing rates, and when ESR1 mutations emerge during first-line (1 L) treatment.</p><p><strong>Methods: </strong>This retrospective, observational cohort study used the Flatiron Health Research Database (FHRD) and the Flatiron Health-Foundation Medicine metastatic breast cancer (mBC) Clinico-Genomic Database (CGDB). Adult patients with a confirmed diagnosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative mBC from 1/1/2018 to 6/30/2024 were included. ESR1 testing patterns and test results were descriptively analyzed.</p><p><strong>Results: </strong>Among 7772 patients with mBC in the FHRD who initiated 1 L therapy, tumor ESR1 mutation status was evaluated for 222 (3%) patients at baseline (≤ 90 days before 1 L) and 1355 (17%) during 1 L. The percentage of patients who had an ESR1 test result reported during 1 L increased over time (11% in 2018-19, 19% in 2020-21, 22% in 2022-24). Median time from 1 L start to first ESR1 test was 7.4 months (mos) among tested patients. A positive test result was reported for 29/222 (13%) patients tested at baseline and 240/1355 (18%) tested during 1 L. Most (60%) tests during 1 L used tissue specimens, while the remaining 40% were liquid biopsies, and the median time from specimen collection to result reporting in 1 L was 28 (IQR:10-84) days. Focusing on time periods wherein specimens were provided, ESR1 test positivity was 6.7% (76/1,127) for specimens provided at baseline, 23% (15/65) for specimens provided 9 to 12 months into 1L therapy, 38% (26/69) for those provided 15 to 18 months into 1L, and 40% (38/94) for those provided from 18 to 24 months into 1L.</p><p><strong>Conclusions: </strong>ESR1 mutations can be detected at any time interval during 1L.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"219 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024.","authors":"Jane L Meisel, Clara Chen, Ayush Kris, Meng Ru, Timothy Pham, James Roose","doi":"10.1007/s10549-026-08061-w","DOIUrl":"10.1007/s10549-026-08061-w","url":null,"abstract":"<p><strong>Purpose: </strong>Clinical studies have highlighted the potential utility of monitoring for Estrogen receptor alpha 1 (ESR1) mutation (m) (ESR1m) emergence during first-line therapy (1L) for metastatic breast cancer (mBC). However, less is known about the real-world practice for patients with emergent ESR1m before progression and their outcomes. This study aimed to characterize real-world treatment patterns among patients with mBC who underwent ESR1m mutation testing during first-line (1L) therapy, and to evaluate the association between ESR1m detection during 1L and clinical outcomes.</p><p><strong>Methods: </strong>This retrospective, observational cohort study used the US-based, deidentified Flatiron Health Research Database and included patients diagnosed with ER+/human epidermal growth factor receptor 2-negative (HER2-) metastatic BC between 2018 and June 2024. rwOS and rwPFS were estimated using the Kaplan-Meier methodology and compared after propensity score matching. Clinical outcomes were evaluated from the time of first ESR1 test during 1L therapy to minimize time-related bias.</p><p><strong>Results: </strong>7772 patients who initiated 1L therapy were included. Treatment patterns in 1L were comparable between patients with (n = 240) and without (n = 1095) ESR1m detected during 1L. Among patients tested for ESR1m mutations during 1L, detection of ESR1m was associated with significantly shorter rwPFS and OS from the time of testing, both before and after propensity score matching (rwPFS hazard ratio [HR] 0.68 [95%CI: 0.48-0.96], rwOS HR: 0.58 [95%CI: 0.36-0.95]).</p><p><strong>Conclusions: </strong>Detection of ESR1m during 1L was associated with poorer clinical outcomes. These findings highlight the clinical relevance of ESR1m emergence prior to progression and underscore the need for strategies to better identify and manage patients with emerging endocrine resistance.</p><p><strong>Clinical trial: </strong>Not applicable.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"219 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study.","authors":"Jingze Liu, Linxiaoxiao Ding, Jiayi Wang, Tao Chen, Tianzhu Long, Qian Li, Jie Chai, Herui Yao, Ying Wang, Jianli Zhao","doi":"10.1007/s10549-026-08070-9","DOIUrl":"10.1007/s10549-026-08070-9","url":null,"abstract":"<p><strong>Purpose: </strong>Although Trop-2 antibody-drug conjugates (ADCs) have improved outcomes in pretreated metastatic triple-negative breast cancer (mTNBC), resistance remains common and the optimal combination strategy in routine practice is unclear.</p><p><strong>Methods: </strong>In this retrospective real-world study, we identified patients with mTNBC from a health record-derived database who received sacituzumab govitecan or sacituzumab tirumotecan in the later-line setting between April 2020 and December 2025. Patients received at least two cycles of Trop-2 ADC therapy as monotherapy, plus a PD-1 inhibitor (dual-agent combination), or plus a PD-1 inhibitor and an antiangiogenic agent (triple-agent combination).</p><p><strong>Results: </strong>Descriptively, the ORR was 57.1% in the triple-agent combination group, 38.5% in the dual-agent combination group, and 31.7% in the monotherapy group. Median follow-up was 15.2 months (95% CI, 8.7-20.6). Median progression-free survival (mPFS) was 15.4 months (95% CI, 5.3-NA) in the triple-agent combination group, 10.0 months (95% CI, 4.2-NA) in the dual-agent combination group, and 3.8 months (95% CI, 3.2-5.2) in the monotherapy group. Severe treatment-related toxicity was not increased in the combination groups. Exploratory analyses identified a genomic scoring system that may enable stratification of patients with a higher likelihood of benefiting from the triple-agent combination.</p><p><strong>Conclusion: </strong>To our knowledge, this study represents one of the earliest real-world evaluations of this triple-agent strategy in previously treated mTNBC, providing a basis for further prospective validation and biomarker-guided application.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"219 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes.","authors":"Matthew R Kroll, Mary C Schroeder, Joan M Neuner, Brahmendra R Viyyuri, Aditya Ravindra, Dana McDougall, Cole G Chapman, Nicole M G Fleege, Elizabeth A Chrischilles, Xing Song, Sneha Phadke","doi":"10.1007/s10549-026-08071-8","DOIUrl":"10.1007/s10549-026-08071-8","url":null,"abstract":"<p><strong>Purpose: </strong>Triple‑negative breast cancer (TNBC) is an aggressive disease with poor survival outcomes. With the integration of immunotherapy, the optimal neoadjuvant chemotherapy backbone remains poorly defined. We examined real-world treatment patterns and response rates among patients receiving a carboplatin-based regimen, with or without anthracyclines.</p><p><strong>Methods: </strong>In this retrospective cohort study, women diagnosed 2012-2024 with stage I-III TNBC who received neoadjuvant carboplatin plus taxane (CbT) or CbT with anthracyclines (AC-CbT) were identified from electronic health records data from 10 sites within the Greater Plains Collaborative network. Registry-recorded physician assessment of pathologic complete response (pCR) was the primary outcome. Multivariable logistic regression evaluated whether adding anthracyclines to carboplatin-based treatment was associated with pCR.</p><p><strong>Results: </strong>Among 878 patients with TNBC, 41.2% received CbT and 58.8% received AC-CbT. Overall, 46% received pembrolizumab, 11.7% in the CbT group and 66.3% in the AC-CbT group. On univariate analysis, pCR rates did not differ between the CbT and AC-CbT groups (47.2% vs. 51.9%, OR = 1.21, 95%CI 0.92-1.58), among patients who underwent surgery. In multivariate adjusted analyses, AC-CbT was not associated with higher odds of pCR (aOR = 1.05, 95%CI 0.69-1.59), among patients who underwent surgery. Other patient characteristics associated with pCR included pembrolizumab use, higher-grade disease, lower stage, and age at diagnosis (40-49 versus 60+). Use of carboplatin-containing regimens increased substantially over time.</p><p><strong>Conclusion: </strong>In this real-world cohort, addition of anthracycline to carboplatin-containing regimen was not associated with an improvement in pCR rates. These findings suggest clinical equipoise regarding anthracycline omission in early-stage TNBC, to be validated in prospective trials. Additional work evaluating adherence, toxicity, and long-term outcomes is needed.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"219 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study.","authors":"Qian Chen, Ian Campbell, Mark Elwood, Alana Cavadino, Phyu Sin Aye, Sandar Tin Tin","doi":"10.1007/s10549-026-08072-7","DOIUrl":"10.1007/s10549-026-08072-7","url":null,"abstract":"<p><strong>Introduction: </strong>Use of adjuvant endocrine therapy (ET) for ductal carcinoma in situ (DCIS) varies widely in clinical practice. We investigated oestrogen receptor (ER) testing, the initiation of ET, and the effect of ET on outcomes for DCIS in New Zealand.</p><p><strong>Methods: </strong>Women with DCIS (2000-2022) were identified from the New Zealand Breast Cancer Foundation National Register and linked to the national pharmaceutical data. Logistic regression identified factors associated with ER testing, and cumulative incidence of breast cancer events was estimated with death as a competing risk.</p><p><strong>Results: </strong>Among 5813 women with DCIS, 894 patients (15.4%) had ER testing, with the rate increasing from 11.1% in 2000 to 23.3% in 2006, before declining to 13.9% in 2022. The Waikato region contributed 65.6% of ER tests. In Waikato, testing was more likely among women who received adjuvant radiotherapy after breast-conserving surgery, likely reflecting a site-specific clinical practice. In other regions, testing was more frequent among older women, Māori ethnicity, those with symptomatic presentation, and those with DCIS size > 20 mm, potentially reflecting selective testing. Among 729 patients with ER-positive DCIS, only 183 (25.1%) commenced ET, of whom 80.3% were in Waikato. ET users had the lowest cumulative risk of breast cancer event, but differences were not statistically significant.</p><p><strong>Conclusions: </strong>ER testing and initiation of ET for DCIS remained low, except in Waikato, where clinical centres participated in ET trials and ER testing became more common. Standardised ER testing and greater clinician participation in clinical trials may lead to improved evidence-based care.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"219 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13538164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}